Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05605535
- Locations
- 🇮🇳
King George Hospital, Visakhapatnam, Andhra Pradesh, India
🇮🇳Omega Hospitals, Visakhapatnam, Andhra Pradesh, India
🇮🇳Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat, India
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05335993
- Locations
- 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Stephenson Cancer Center- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04938583
- Locations
- 🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Korea Anam Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 615
- Registration Number
- NCT04498117
- Locations
- 🇺🇸
Minnesota Oncology Hematology - Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸University Hospitals of Cleveland, Cleveland, Ohio, United States
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03162562
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
🇺🇸VCU Massey Cancer Center, Dalton Oncology Clinic, Richmond, Virginia, United States